New heart valve device offers hope for patients too sick for surgery

NCT ID NCT06683729

Not yet recruiting Disease control Sponsor: HighLife SAS Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new device called the HighLife TSMVR system for people with severe mitral regurgitation, a condition where the heart's mitral valve leaks. The device is placed through a catheter via a vein, avoiding open-heart surgery. The trial will include 240 participants who are not candidates for standard repair or surgery, and will track safety and effectiveness over 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: transcatheter mitral valve replacement device
What this could lead to: If successful, this could provide a new treatment option for people with severe mitral regurgitation who cannot have standard surgery or repair.
What could go wrong: This is an early study with 240 participants, and the device is new. Risks include complications from the procedure, device failure, or no benefit over existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MITRAL VALVE (MV) REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease mitral valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MITRAL VALVE (MV) REGURGITATION

More trials for these conditions

Other studies related to the condition(s) this trial covers.